Visual field loss associated with vigabatrin: Pathological correlations

Journal of Neurology Neurosurgery and Psychiatry

Volumn 70, Issue 6, 2001, Pages 787-789

  Ravindran, J ^a   Blumbergs, P ^d   Crompton, J ^b   Pietris, G ^c   Waddy, H ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b Neuro ophthalmology Service

^c Ophthalmology Unit   (Italy)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Retina; Vigabatrin; Visual field

Indexed keywords

VIGABATRIN;

ADULT; ARTICLE; CASE REPORT; COMPLEX PARTIAL SEIZURE; DRUG EFFECT; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; GABAERGIC TRANSMISSION; HISTOPATHOLOGY; HUMAN; MALE; MEDIATOR RELEASE; NEUROTRANSMITTER RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA GANGLION CELL; VISUAL FIELD DEFECT;

ADULT; ANTICONVULSANTS; EPILEPSY, COMPLEX PARTIAL; HUMANS; MALE; RETINA; VIGABATRIN; VISUAL FIELDS; VISUAL PATHWAYS;

EID: 0034984516     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.70.6.787     Document Type: Article

References (15)

1. Petroff OA, Rothman DL. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. Mol Neurobiol 1998;16:97-121.
2. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314: 180-1.
3. Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-6.
4. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67:716-22.
5. Harding GF. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist [letter]. BMJ 1997;314:1694.
6. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27:43-5S.
7. Cohen JA, Fisher RS, Brigell MG, et al. The potential for vigabatrin-induced intramelinic edema in humans. Epilepsia 2000;41:148-57.
8. Wild MJ, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999;40:1784-94.
9. Sadun AA. Anatomy and physiology of the optic nerve. In: Miller NR, Newman NJ, eds. Walsh and Hoyt's clinical neuro-ophthalmology. 5th ed. Philadelphia: Williams and Wilkins; 1997;1:57-85.
10. Van Haesendonck E, Missotten L. A subgroup of bipolar cells in the human retina is GABA-immunoreactive. Neurosci Lett 1993;161:187-90.
11. Baulac M, Nordmann J-P, Lanoe Y. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet 1998;352:546.
12. Krauss GL, Johnson MA, Miller NR. Vigabatrin associated retinal cone system dysfunction. Neurology 1998;50:614-18.
13. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiological findings. Neurology 1999;53:2082-7.
14. Arndt CF, Derambure P, Defoort-Dhellemmes S, et al. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999;52:1201-5.
15. Hirsch E. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 2000;54:1396.